Disparities in cardiovascular disease mortality after breast cancer treatment: methodological considerations using real-world data Published December 2021 Citation Calip, GS, Brown-Wade, N, Guadamuz, JS, Wang, X, Miksad, RA, Whitaker, K. . Cancer. . https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34045 Authors:Calip, GS, Brown-Wade, N, Guadamuz, JS, Wang, X, Miksad, RA, Whitaker, K Sources:Cancer Share Posted inPublicationsHealth equityBreast cancer More publicationsAACR Special Conference in Cancer Research: Artificial Intelligence and Machine LearningJuly 2025Fairness by design: End-to-end bias evaluation for LLM-generated dataEstevez M, Mbah O, Sheikh A, et al.Publication summaryPublicationsData scienceHealth equityBreast cancerArtificial intelligenceESMOOctober 2025Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practiceBrufsky A, Layman R, Liu X, et al.Publication summaryPublicationsComparative effectivenessBreast cancerESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancer